Comparative Pharmacology
Head-to-head clinical analysis: MEGACE ES versus NORETHINDRONE AND MESTRANOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MEGACE ES versus NORETHINDRONE AND MESTRANOL.
MEGACE ES vs NORETHINDRONE AND MESTRANOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Megestrol acetate is a synthetic progestin that inhibits pituitary gonadotropin secretion, leading to suppression of ovarian and testicular hormone production. It also has antineoplastic effects possibly through local action on hormone-sensitive tissues and stimulates appetite via modulation of neuropeptide Y and other appetite-regulating factors.
Norethindrone is a progestin that suppresses gonadotropin secretion, primarily luteinizing hormone (LH), thereby inhibiting ovulation. Mestranol is a prodrug of ethinyl estradiol, an estrogen that provides negative feedback on the hypothalamic-pituitary-ovarian axis, further suppressing follicle-stimulating hormone (FSH) and LH. The combination stabilizes the endometrium and alters cervical mucus consistency to impede sperm penetration.
625 mg orally once daily (MEGACE ES suspension contains 625 mg/5 mL; shake well before use). For appetite stimulation in cachexia.
1 tablet (norethindrone 1 mg / mestranol 0.05 mg) orally once daily for 21 days, then 7 days off.
None Documented
None Documented
Approximately 34 hours in plasma; steady-state achieved after 2-3 weeks of daily dosing.
Norethindrone: 5-12 hours; Mestranol: 50-120 minutes (mestranol is rapidly demethylated to ethinyl estradiol, which has a half-life of 10-20 hours). Clinical context: Steady-state is achieved within 5-7 days; no clinically significant accumulation under normal dosing.
Primarily renal (≤1% unchanged) and biliary; extensive metabolism to inactive glucuronide conjugates excreted in feces.
Renal (30-50% as metabolites), biliary/fecal (35-55% as metabolites and conjugated forms).
Category C
Category D/X
Progestin
Progestin